ohnson & Johnson has concluded a ‘catapult year’ with $94.2 billion in revenue, driven by a surge in oncology sales and strategic MedTech innovations. As the healthcare giant prepares to spin off its orthopaedics business, it sets its sights on becoming the first healthcare company to surpass the $100 billion annual revenue milestone in 2026.
Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156). [Read More…]
AbbVie and Genmab have announced significant topline results from the pivotal Phase 3 EPCORE® DLBCL-1 trial. The study marks a clinical milestone as the first Phase 3 trial to demonstrate a statistically significant improvement in progression-free survival (PFS) for a CD3xCD20 bispecific antibody monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Novartis reaches a historic milestone in immunology as the FDA grants Breakthrough Therapy designation to ianalumab for Sjögren’s disease. Backed by successful Phase III NEPTUNUS trials, this dual-action monoclonal antibody is poised to become the first targeted therapy for this chronic autoimmune condition. With global regulatory submissions planned for early 2026, ianalumab represents a significant leap forward for millions of patients currently facing an immense unmet medical need.
Johnson & Johnson (NYSE: JNJ) today announced groundbreaking topline results from the Phase 3 MajesTEC-9 study, demonstrating that TECVAYLI® (teclistamab-cqyv) monotherapy significantly improves outcomes for [Read More…]
Imagine trying to communicate with someone who speaks the same language but uses a different dialect. You both understand the words, but some phrases might [Read More…]
In a major shift for the pharmaceutical industry, AbbVie (NYSE: ABBV) announced on Monday a sweeping, voluntary agreement with the Trump administration designed to lower [Read More…]
NVIDIA and Eli Lilly have unveiled a landmark $1 billion partnership to launch a first-of-its-kind AI co-innovation lab in the San Francisco Bay Area. By co-locating world-class scientists and AI engineers, the collaboration aims to “industrialize” drug discovery through advanced foundation models, robotics, and “lab-in-a-loop” workflows.
In a move that signals a significant shift in the relationship between Big Pharma and the federal government, Johnson & Johnson (NYSE: JNJ) announced a [Read More…]
Eli Lilly expands its clinical-stage portfolio with the $1.2 billion acquisition of Ventyx Biosciences, securing high-potential oral NLRP3 inhibitors to treat chronic inflammation and neurodegenerative disorders.
